Gene therapy hypertension

Pachori AS, Numan MT, Ferrario CM, Diz DM, Raizada MK, Katovich MJ, Blood pressure-independent attenuation of cardiac hypertrophy by AT( I )R-AS gene therapy, Hypertension 2002 20 969-975. 

Y. Tang, M. Jackson, K. Qian and M.I. Phillips, Hypoxia inducible double plasmid system for myocardial ischemia gene therapy, Hypertension 39(2), 695-698 (2002). 

Reynolds, A.M., Xia, W., Holmes, M.D., Hodge, S.J., Danilov, S., Curiel, D.T., Morrell, N.W., and Reynolds, P.N. (2007) Bone morphogenetic protein type 2 receptor gene therapy attenuates hypoxic pulmonary hypertension. Am. J. Physiol. Lung Cell Mol. Physiol. 292, L1182-L1192. 

Liu L, Liu H, Visner G, Fletcher BS. 2006. Sleeping beauty-mediated eNOS gene therapy attenuates monocrotaline-induced pulmonary hypertension in rats. FASEB J. 20 2594-2596. 

Raizada MK, Der-Sarkissian S. 2006. Potential of gene therapy strategy for the treatment of hypertension. Hypertension. 47 6-9. 

Schillinger KJ, Tsai SY, Taffet GE, Reddy AK, et al. 2006. Regulatable atrial natriuretic peptide gene therapy for hypertension. Proc Nat Acad Sci USA. 27 13789-13794. 

Pulmonary gene therapy is attractive for the treatmment of chronic bronchitis, cystic fibrosis, a-1 antitrypsin deficiency, familial emphysema, asthma, pulmonary infections, surfactant deficiency, pulmonary hypertension, lung cancer, and malignant mesothelioma. The pulmonary endothelium may act as a bioreactor for the production and secretion of therapeutic proteins, such as clotting factors and erythropoietin into the blood circulation. There is a potential benefit for acquired lung diseases, as well as cancers, to be controlled and possibly treated by expression of cytokines, surfactant, antioxidant enzymes, or mucoproteins within lung cells. 

Lancet 353 1341-1347 Vaughan O J, Delanty N 2000 Hypertensive emergencies. Lancet 356 411 17 Yla-Herttuala S, Martin J F 2000 Cardiovascular gene therapy. Lancet 355 213-222... 

Zhao YD, Courtman DW, Deng Y, et al. Rescue of monocro-taline-induced pulmonary arterial hypertension using bone marrow-derived endothelial-like progenitor cells efficacy of combined cell and eNOS gene therapy in established disease. Circ Res 2005 96 442-50. 

Nagaya, N., Kangawa, K., Kanda, M, Uematsu, M., Horio, T., Fukuyama, N., Hino, J., Harada-Shiba, M., Okumura, H., Tabata, Y., Mochizuki, N., Chiba, Y, Nishioka, K., Miyatake, K., Asahara, T., Hara, H., and Mori, H. 2003. Hybrid cell - gene therapy for pulmonary hypertension based on phagocytosing action of endothelial progenitor cells. Circulation, 108,889-895. 

NicHin SA, Reynolds PN, Brosnan MJ, White SJ, Curiel DT, Dominiezak AF, Baker AH. Analysis of cell-specific promoters for viral gene therapy targeted at the vasctrlar endothelirrm. Hypertension 2001 38 65-70. 

V. Using the Airway for Gene Therapy of Pulmonary Hypertension... 

Psaty, B.M., et al., "Diuretic Therapy, the -Adducin Gene Variant, and the Risk of Myocardial Infarction or Stroke in Persons with Treated Hypertension," JAMA, 287, 1680-1689 (2002). 

Puddu GM, Cravero E, Ferrari E, Muscari A, et al. 2007. Gene based therapy for hypertension -Do preclinical data suggest a promising future Cardiology. 108 40-47. 

Pulmonary hypertension is a devastating, potentially fatal disorder. Recent years have witnessed a great expansion in our understanding of the molecular pathophysiology of this condition. Options for therapy have just become available in recent years, focused either on the prostacyclin pathway or the nitric oxide pathway for pulmonary arteriolar relaxation. Continuous infusion of prostacyclin has been successful, demonstrating the relevance of the former pathway. The efficacy of both inhaled nitric oxide and systemic sildenafil support the latter. In the future, gene transfer could be used for sustained delivery of either of these agents, by means of... 

---